Wang Zu-sen, Wu Li-qun, Yi Xin, Geng Chao, Li Yu-jun, Yao Ru-yong, Hu Wei-yu, Han Bing
Department of Hepatobiliary Surgery, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China.
Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):753-8. doi: 10.3760/cma.j.issn.0253-3766.2012.10.008.
To investigate the expression of CK19 in HBV-related hepatocellular carcinoma (HCC) tissues in patients with low serum AFP concentration and the relationship between them and the recurrence and prognosis of HCC after R0 radical hepatectomy.
The expressions of CK19 and Ki67 in HCC tissues of 235 cases were examined using tissue microarray and two-step methods of PV-6000 immunohistochemistry. The expression of CK19 mRNA in 20 frozen HCC specimens was examined by RT-PCR. The correlation between gene expressions and tumor recurrence and prognosis was analyzed.
Among the 235 HBV-related HCC patients after R0 radical hepatectomy, the median disease-free survival (DFS) was 31.2 months in the patients with serum AFP < 400 µg/L and 13.8 months in the patients with serum AFP ≥ 400 µg/L (P = 0.041), the overall survival (OS) was 84.0 and 58.6 months in the two subgroups (P = 0.125), and the tumor recurrence within one year was in 43 cases (27%) and 37 cases (49.3%), respectively, (P = 0.001). The DFS was 11.6 months in the CK19-positive cases and 27.0 months in the CK19-negative cases (P > 0.05). The OS was significantly lower in the CK19-positive cases than that in the CK19-negative cases (P = 0.023). Both DFS and OS in the CK19-positive cases with AFP < 400 µg/L were significantly lower than those in the CK19-negative cases with AFP < 400 µg/L (both P < 0.05). The CK19 expression was significantly correlated with histological differentiation (P = 0.023), number of tumor foci (P = 0.044), vascular tumor embolism (P = 0.005), regional lymph node metastasis (P = 0.023), and 1-year recurrence (P = 0.006). Among the patients with AFP < 400 µg/L, the 1-year recurrence was 53% in the CK19-positive cases and 23% in the CK19-negative cases (P < 0.001), the median DFS was 11.3 months in CK19-positive cases and 34.0 months in CK19-negative cases (P = 0.010), and the median OS was 19.5 months in the CK19-positive cases, significantly lower than 84.0 months in the CK19-negative cases (P = 0.001). Cox regression analysis showed that CK19-positive expression was an independent factor affecting early HCC recurrence and prognosis.
In HBV-related HCC patients after radical hepatectomy with AFP < 400 µg/L, positive expression of CK19 indicates a higher proliferation and invasiveness of HCC, and is an important factor of early recurrence and poor prognosis.
探讨低血清甲胎蛋白(AFP)浓度的乙肝相关肝细胞癌(HCC)组织中细胞角蛋白19(CK19)的表达情况,以及其与R0根治性肝切除术后HCC复发和预后的关系。
采用组织芯片和PV - 6000免疫组化两步法检测235例HCC组织中CK19和Ki67的表达。采用逆转录聚合酶链反应(RT - PCR)检测20例冷冻HCC标本中CK19 mRNA的表达。分析基因表达与肿瘤复发及预后的相关性。
在235例接受R0根治性肝切除的乙肝相关HCC患者中,血清AFP<400 μg/L患者的中位无病生存期(DFS)为31.2个月,血清AFP≥400 μg/L患者的中位无病生存期为13.8个月(P = 0.041);两个亚组的总生存期(OS)分别为84.0个月和58.6个月(P = 0.125);一年内肿瘤复发分别为43例(27%)和37例(49.3%)(P = 0.001)。CK19阳性病例的DFS为11.6个月,CK19阴性病例的DFS为27.0个月(P>0.05)。CK19阳性病例的OS显著低于CK19阴性病例(P = 0.023)。血清AFP<400 μg/L的CK19阳性病例的DFS和OS均显著低于血清AFP<400 μg/L的CK19阴性病例(均P<0.05)。CK19表达与组织学分化(P = 0.023)、肿瘤灶数量(P = 0.044)、肿瘤血管栓塞(P = 0.005)、区域淋巴结转移(P = 0.023)及1年复发率(P = 0.006)显著相关。在血清AFP<400 μg/L的患者中,CK19阳性病例的1年复发率为53%,CK19阴性病例的1年复发率为23%(P<0.001);CK19阳性病例的中位DFS为11.3个月,CK19阴性病例的中位DFS为34.0个月(P = 0.010);CK19阳性病例的中位OS为19.5个月,显著低于CK19阴性病例的84.0个月(P = 0.001)。Cox回归分析显示,CK19阳性表达是影响早期HCC复发和预后的独立因素。
在血清AFP<400 μg/L的乙肝相关HCC根治性肝切除术后患者中,CK19阳性表达提示HCC具有较高的增殖和侵袭性,是早期复发和预后不良的重要因素。